---
title: See which exercise improves balance
nct_id: NCT07662837
phase: NA
status: RECRUITING
sponsor: Lahore University of Biological and Applied Sciences
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07662837"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07662837"
last_fetched: "2026-06-23T14:02:04.845Z"
source: "Parkinson's Pathways (curated)"
---
# See which exercise improves balance

**Goal (in five words):** See which exercise improves balance

**Official Title:** Effects of Tai Chi Therapy Versus Qi-Gong on Postural Control, Functional Balance , and Motor Function in Stage-I Parkinson's Patients.

**Trial ID:** [NCT07662837](https://clinicaltrials.gov/study/NCT07662837)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Lahore University of Biological and Applied Sciences
- **Target Enrollment:** 50 participants
- **Start Date:** 2026-05-30
- **Completion Date:** 2026-08-30
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** Tai Chi, Qi Gong
- **Intervention Types:** OTHER

## Summary For Families

Researchers are comparing Tai Chi and Qi-Gong to see which movement therapy better improves posture, balance, and overall movement in people with early, Stage I Parkinson's, and which one people are more likely to keep doing. Participants are randomly assigned to one of the two programs for about 8 to 12 weeks, with measurements taken before and after using standard tools like the Unified Parkinson's Disease Rating Scale and the Berg Balance Scale. The study also looks at patient-centered outcomes such as how people perceive the exercise to help guide practical physiotherapy choices. Adults aged 50 to 65 with Stage I Parkinson's who have been on a stable Parkinson's medication dose for at least three months, can do basic self-care, and have no significant cognitive problems are eligible; people with significant depression, recent deep brain stimulation, certain medications that affect thinking or alertness, or who are already in an exercise program are excluded.

## What This Actually Involves

**Placebo** _(From the protocol)_: There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.

**Visits** _(From the protocol)_: Assessments are recorded at baseline and post-intervention, and the study lasts 8 to 12 weeks.
  > "The study duration is expected to span 8 to 12 weeks, allowing sufficient time for neuromuscular adaptations and observable functional improvements while maintaining feasibility and participant compliance. Outcome measures include standardized and validated tools such as the Unified Parkinson's Disease Rating Scale for assessing disease severity, the Berge Balance Scale is use for the functional balance and postural control these measures are recorded at baseline and post-intervention"

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Diagnosis of PD based on the Hoehn \& Yahr staging system (Stages I). Male or female patients aged between 50-65 years. Currently receiving stable anti-Parkinsonian medication, with no changes in the treatment regimen for at least 3 months. Basic self-care ability with no severe cognitive impairment (Mini-Mental State Examination \[MMSE\] score ≥24).

Exclusion Criteria:

Depression, as assessed based on a score of \>16 for the Beck Depression Inventory-II (BDI-II). Recent deep brain stimulation (DBS) treatment. Use of medication that interferes with cognition, alertness, or attention. Current participation in an exercise training program.
```

## Locations (2)

- Ghurki Trust and Teaching Hospital, Lahore, Punjab Province, Pakistan _(31.5580, 74.3507)_
  - Dr. Mir Shakeel Ahmad, (CONTACT)
- The Meer's Physiotherapy and Rehabilitation, Lahore, Pakistan _(31.5580, 74.3507)_
  - Salwa Atta, (CONTACT), 03084579229, salwa.atta@ubas.edu.pk

## Central Contacts

- Maryam Fayyaz, (CONTACT), 03374677916, maryamfayyazawan@gmail.com
- Salwa Atta, (CONTACT), 03084579229

---

*Canonical: https://parkinsonspathways.com/trial/NCT07662837*  
*HTML version: https://parkinsonspathways.com/trial/NCT07662837*  
*Source data: https://clinicaltrials.gov/study/NCT07662837*